Altimmune AI Price Prediction

Altimmune is currently unprofitable, as indicated by its negative EPS and PE ratio. The lack of positive earnings suggests that the company is still in a cash‑consuming, development-heavy phase rather than a mature, revenue-generating stage. Until there is clear visibility on a path to profitability or significant revenue growth, the financial profile remains high risk.

• Negative EPS of -1.07 and a PE ratio of -3.37 indicate ongoing losses and no current earnings support for the stock.
• The valuation is driven primarily by expectations for future pipeline success rather than current revenue or profit fundamentals.
• Without evidence of improving margins, growing revenue, or narrowing losses, the financial picture leans speculative and fundamentally weak in the near term.

The stock has fallen 24.2% over the last month and is trading below its 200‑day moving average, signaling a broader downtrend. An RSI near 70 suggests the stock is close to overbought on a short‑term basis despite the longer-term weakness, which can create unfavorable risk‑reward for new entries. Overall, technicals point to a pressured name with limited confirmation of a durable reversal.

• Current price of $3.61 is meaningfully below the 200‑day moving average of $4.61, indicating a prevailing longer‑term downtrend.
• A 24.2% decline over the past month reflects strong negative momentum and recent selling pressure.
• RSI at 69.89 is near overbought territory, suggesting any recent bounce may be stretched and vulnerable to pullbacks within a broader weak trend.

Altimmune’s stock currently reflects a speculative, loss‑making profile with weak technicals and only neutral alternative data support. The combination of negative earnings, a recent sharp price decline, trading below the 200‑day moving average, and only modest engagement growth suggests a cautious stance is warranted. Until there is clearer evidence of improving fundamentals or a sustained technical reversal, the overall outlook leans bearish.

• Unprofitable financials and a negative PE ratio leave the stock dependent on future expectations rather than current performance.
• Price action and technical indicators point to a weak trend with elevated near‑term risk, while alternative data are stable but not strongly supportive of a growth inflection.